(NYSE: OGN) Organon & Co's forecast annual revenue growth rate of 1.21% is not forecast to beat the US Drug Manufacturers - General industry's average forecast revenue growth rate of 8.52%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 23.4%.
Organon & Co's revenue in 2026 is $6,301,000,000.On average, 7 Wall Street analysts forecast OGN's revenue for 2026 to be $1,622,813,336,704, with the lowest OGN revenue forecast at $1,512,580,582,016, and the highest OGN revenue forecast at $1,729,406,330,624. On average, 6 Wall Street analysts forecast OGN's revenue for 2027 to be $1,634,512,567,744, with the lowest OGN revenue forecast at $1,507,380,923,776, and the highest OGN revenue forecast at $1,753,844,724,352.
In 2028, OGN is forecast to generate $1,719,786,962,880 in revenue, with the lowest revenue forecast at $1,643,351,986,752 and the highest revenue forecast at $1,814,940,708,672.